Articles
Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SURPASS-CVOT Design and Baseline Characteristics
Nicholls SJ, Bhatt DL, Buse JB, et al.
Journal:
Am Heart J
First published: September 25, 2023 DOI: 10.1016/j.ahj.2023.09.007